PARK7 and Alzheimer disease: Another compound, Compound-B, has subsequently been tested in a transgenic mouse model of AD and found to improve spatial learning, memory, and amyloid-β clearance, thus suggesting for the first time that DJ-1 compounds may have applications for AD treatment [87].